European Union (Withdrawal) Act 2018

Ferguson plc (“Company”): Director/PDMR Shareholding

Retrieved on: 
Tuesday, October 17, 2023
Professional Services, HVAC, Other Construction & Property, Manufacturing, Finance, Construction & Property, Other Manufacturing, European Union (Withdrawal) Act 2018, Pharmaceutical industry, Medical device

The awards were granted as restricted stock units.

Key Points: 
  • The awards were granted as restricted stock units.
  • No consideration is payable at allocation or on vesting.
  • The awards have no performance conditions and will normally vest, only subject to continued service to the Company, on October 12, 2024.
  • The attached notifications, which have been made in accordance with the requirements of the EU Market Abuse Regulation (as it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018), provide further detail.

Transaction in Own Shares

Retrieved on: 
Monday, October 16, 2023
European, European Union (Withdrawal) Act 2018, Market abuse, Listing Rules, Withdrawal, European Union (Withdrawal Agreement) Act 2020, Financial Services Act, Financial Services Act 2013, Shell, Brexit, EU

These share purchases form part of the on- and off-market limbs of the Company's existing share buy-back programme previously announced on 27 July 2023.

Key Points: 
  • These share purchases form part of the on- and off-market limbs of the Company's existing share buy-back programme previously announced on 27 July 2023.
  • In respect of this programme, Citigroup Global Markets Limited will make trading decisions in relation to the securities independently of the Company for a period from 27 July 2023 up to and including 27 October 2023.
  • The on-market limb will be effected within certain pre-set parameters and in accordance with the Company’s general authority to repurchase shares on-market.
  • The off-market limb will be effected in accordance with the Company’s general authority to repurchase shares off-market pursuant to the off-market buyback contract approved by its shareholders and the pre-set parameters set out therein.

Transaction in Own Shares

Retrieved on: 
Friday, October 13, 2023
European, European Union (Withdrawal) Act 2018, Market abuse, Listing Rules, Withdrawal, European Union (Withdrawal Agreement) Act 2020, Financial Services Act, Financial Services Act 2013, Shell, Brexit, EU

These share purchases form part of the on- and off-market limbs of the Company's existing share buy-back programme previously announced on 27 July 2023.

Key Points: 
  • These share purchases form part of the on- and off-market limbs of the Company's existing share buy-back programme previously announced on 27 July 2023.
  • In respect of this programme, Citigroup Global Markets Limited will make trading decisions in relation to the securities independently of the Company for a period from 27 July 2023 up to and including 27 October 2023.
  • The on-market limb will be effected within certain pre-set parameters and in accordance with the Company’s general authority to repurchase shares on-market.
  • The off-market limb will be effected in accordance with the Company’s general authority to repurchase shares off-market pursuant to the off-market buyback contract approved by its shareholders and the pre-set parameters set out therein.

Mydecine Innovations Group Announces Admission to Trading on the AQSE Growth Market in London, UK

Retrieved on: 
Thursday, October 12, 2023
Psilocybin, University, MAR, OTC, European Union (Withdrawal) Act 2018, Health care, Investigational New Drug, CDI, Interest, MDMA, PTSD, Indian stock exchange, Novel, Biotechnology, Half-life, Financial Conduct Authority, CREST, Mental health, Issuer, Admission, FSE, PCT, Access, ISIN, NEO, Patent Cooperation Treaty, MYIG, Pharmaceutical industry, Security (finance), EU

Mydecine Innovations Group Inc. is an emerging biotech and life sciences company dedicated to developing and commercializing innovative solutions for treating mental health problems and enhancing wellbeing.

Key Points: 
  • Mydecine Innovations Group Inc. is an emerging biotech and life sciences company dedicated to developing and commercializing innovative solutions for treating mental health problems and enhancing wellbeing.
  • The Companies various families of Novel 2nd generation molecules are showing significant improvements over the first generation of psychedelic treatments.
  • Josh Bartch, CEO of the Company stated, “We are incredibly excited to list our securities for trading in the UK on the AQSE Growth Market.
  • This announcement, together with any documents incorporated by reference, shall be deemed to constitute an admission document for the purposes of the AQSE Growth Market Rules for Issuers – Access.

Transaction in Own Shares

Retrieved on: 
Thursday, October 12, 2023
European, European Union (Withdrawal) Act 2018, Market abuse, Listing Rules, Withdrawal, European Union (Withdrawal Agreement) Act 2020, Financial Services Act, Financial Services Act 2013, Shell, Brexit, EU

These share purchases form part of the on- and off-market limbs of the Company's existing share buy-back programme previously announced on 27 July 2023.

Key Points: 
  • These share purchases form part of the on- and off-market limbs of the Company's existing share buy-back programme previously announced on 27 July 2023.
  • In respect of this programme, Citigroup Global Markets Limited will make trading decisions in relation to the securities independently of the Company for a period from 27 July 2023 up to and including 27 October 2023.
  • The on-market limb will be effected within certain pre-set parameters and in accordance with the Company’s general authority to repurchase shares on-market.
  • The off-market limb will be effected in accordance with the Company’s general authority to repurchase shares off-market pursuant to the off-market buyback contract approved by its shareholders and the pre-set parameters set out therein.

Caledonia Mining Corporation Plc: Record Quarterly Production at Blanket Mine

Retrieved on: 
Wednesday, October 11, 2023
Mining, Terrorism, MAR, COVID-19, European Union (Withdrawal) Act 2018, Technical report, Australian Capital Television Pty Ltd v Commonwealth, Insurance, Coronavirus, Safety, Legislation, Mineral, SEDAR, News, Nationalization, Sale, Infection, Cryptocurrency, EU

596/2014 (“MAR”) as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 and is disclosed in accordance with the Company's obligations under Article 17 of MAR.

Key Points: 
  • 596/2014 (“MAR”) as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 and is disclosed in accordance with the Company's obligations under Article 17 of MAR.
  • Security holders, potential security holders and other prospective investors are cautioned not to place undue reliance on forward-looking information.
  • Caledonia undertakes no obligation to update publicly or otherwise revise any forward-looking information whether as a result of new information, future events or other such factors which affect this information, except as required by law.
  • This news release is not an offer of the shares of Caledonia for sale in the United States or elsewhere.

Transaction in Own Shares

Retrieved on: 
Wednesday, October 11, 2023
European, European Union (Withdrawal) Act 2018, Market abuse, Listing Rules, Withdrawal, European Union (Withdrawal Agreement) Act 2020, Financial Services Act, Financial Services Act 2013, Shell, Brexit, EU

These share purchases form part of the on- and off-market limbs of the Company's existing share buy-back programme previously announced on 27 July 2023.

Key Points: 
  • These share purchases form part of the on- and off-market limbs of the Company's existing share buy-back programme previously announced on 27 July 2023.
  • In respect of this programme, Citigroup Global Markets Limited will make trading decisions in relation to the securities independently of the Company for a period from 27 July 2023 up to and including 27 October 2023.
  • The on-market limb will be effected within certain pre-set parameters and in accordance with the Company’s general authority to repurchase shares on-market.
  • The off-market limb will be effected in accordance with the Company’s general authority to repurchase shares off-market pursuant to the off-market buyback contract approved by its shareholders and the pre-set parameters set out therein.

Mydecine Innovations Group Announces Admission to Trading on the AQSE Growth Market in London, UK and First Day of Dealings

Retrieved on: 
Tuesday, October 10, 2023
Psilocybin, University, MAR, OTC, European Union (Withdrawal) Act 2018, Health care, Investigational New Drug, CDI, Interest, MDMA, PTSD, Indian stock exchange, Novel, Half-life, Financial Conduct Authority, CREST, Mental health, Issuer, Admission, CSE, PCT, Access, ISIN, Patent Cooperation Treaty, MYIG, Pharmaceutical industry, Security (finance), EU

Mydecine Innovations Group Inc. is an emerging biotech and life sciences company dedicated to developing and commercializing innovative solutions for treating mental health problems and enhancing wellbeing.

Key Points: 
  • Mydecine Innovations Group Inc. is an emerging biotech and life sciences company dedicated to developing and commercializing innovative solutions for treating mental health problems and enhancing wellbeing.
  • The Companies various families of Novel 2nd generation molecules are showing significant improvements over the first generation of psychedelic treatments.
  • Josh Bartch, CEO of the Company stated, “We are incredibly excited to list our securities for trading in the UK on the AQSE Growth Market.
  • This announcement, together with any documents incorporated by reference, shall be deemed to constitute an admission document for the purposes of the AQSE Growth Market Rules for Issuers – Access.

Transaction in Own Shares

Retrieved on: 
Tuesday, October 10, 2023
European, European Union (Withdrawal) Act 2018, Market abuse, Listing Rules, Withdrawal, European Union (Withdrawal Agreement) Act 2020, Financial Services Act, Financial Services Act 2013, Shell, Brexit, EU

These share purchases form part of the on- and off-market limbs of the Company's existing share buy-back programme previously announced on 27 July 2023.

Key Points: 
  • These share purchases form part of the on- and off-market limbs of the Company's existing share buy-back programme previously announced on 27 July 2023.
  • In respect of this programme, Citigroup Global Markets Limited will make trading decisions in relation to the securities independently of the Company for a period from 27 July 2023 up to and including 27 October 2023.
  • The on-market limb will be effected within certain pre-set parameters and in accordance with the Company’s general authority to repurchase shares on-market.
  • The off-market limb will be effected in accordance with the Company’s general authority to repurchase shares off-market pursuant to the off-market buyback contract approved by its shareholders and the pre-set parameters set out therein.

Transaction in Own Shares

Retrieved on: 
Monday, October 9, 2023
European, European Union (Withdrawal) Act 2018, Market abuse, Listing Rules, Withdrawal, European Union (Withdrawal Agreement) Act 2020, Financial Services Act, Financial Services Act 2013, Shell, Brexit, EU

These share purchases form part of the on- and off-market limbs of the Company's existing share buy-back programme previously announced on 27 July 2023.

Key Points: 
  • These share purchases form part of the on- and off-market limbs of the Company's existing share buy-back programme previously announced on 27 July 2023.
  • In respect of this programme, Citigroup Global Markets Limited will make trading decisions in relation to the securities independently of the Company for a period from 27 July 2023 up to and including 27 October 2023.
  • The on-market limb will be effected within certain pre-set parameters and in accordance with the Company’s general authority to repurchase shares on-market.
  • The off-market limb will be effected in accordance with the Company’s general authority to repurchase shares off-market pursuant to the off-market buyback contract approved by its shareholders and the pre-set parameters set out therein.